Showing 2411-2420 of 9091 results for "".
How to Choose the Right Filler
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/how-to-choose-the-right-filler/19411/Dr. Amy Derick reviews key points about injectable fillers, a non-invasive alternative to surgical facelifts.Dr. Chan Discusses Experience with Gemini Laser
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dr-chan-discusses-experience-with-gemini-laser/19471/“Gemini is an extremely effective non-ablative skin rejuvenation laser. And by combining the 532 KTP lasers with the long pulse 1064 YAG, we can achieve non-ablative skin rejuvenations in terms of reductions of pigmentations, fine lines, pore size and vessel improvement.” & #8212Professor HenryBodyJet Infiltration
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/bodyjet_meyer-infiltration/19520/Demonstration of cannula placement in the anterior and posterior thigh.Nonsurgical Skin Tightening and Facelifts
https://practicaldermatology.com/series/c-suite-chats/nonsurgical-skin-tightening-and-facelifts/54266/Kim Laudati, founder and president of SomaCell, discusses recent demand for minimally invasive, natural-looking treatments and how her company's nonsurgical skin tightening and facelifts help address that trend.DWTV Extra: Skin and Scalp Health
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-skin-and-scalp-health/54147/Chesahna Kindred, MD, MBA, FAAD, discusses an event at the Science of Skin & Scalp Studio in New York, New York, featuring interactive rooms led by dermatologists, beauty experts, and influencers living with chronic inflammatory conditions sharing stories and shaping the conversation around skinEffector Cell Response Inhibitors
https://practicaldermatology.com/series/c-suite-chats/effector-cell-response-inhibitors/48960/Excellergy cofounder Alexander Eggel, PhD, and CEO Todd Zavodnick discuss a recent Journal of Allergy and Clinical Immunology article validating the trifunctional mechanism of action of effector cell response inhibitors (ECRIs) for the treatment of allergic diseases, including chronic spontaneous urEffector Cell Response Inhibitors
https://practicaldermatology.com/series/c-suite-chats/effector-cell-response-inhibitors/48959/Excellergy cofounder Alexander Eggel, PhD, and CEO Todd Zavodnick discuss a recent Journal of Allergy and Clinical Immunology article validating the trifunctional mechanism of action of effector cell response inhibitors (ECRIs) for the treatment of allergic diseases, including chronic spontaneous urImproving Care Options for CTCL
https://practicaldermatology.com/series/c-suite-chats/improving-care-options-for-ctcl/48714/Greg Palko, Vice President, North America, and Oncology Franchise Head for Kyowa Kirin, discusses the challenges posed by cutaneous T-cell lymphoma and efforts to address those issues.The Evolving Needs of the Modern Patient
https://practicaldermatology.com/series/c-suite-chats/the-evolving-needs-of-the-modern-patient/39900/Cutera CEO Taylor Harris talks about the rise of the "multimodality patient," the increasing desire among patients to take control of their healthcare journey, and the rise of regenerative aesthetics, as well as how Cutera is addressing those needs.Dermwire TV: Socioeconomic Neighborhood Status Linked with HS Severity, Plus More
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-socioeconomic-neighborhood-status-linked-with-hs-severity-plus-more/39881/This episode highlights new data linking neighborhood socioeconomic status to hidradenitis suppurativa severity, as well as a new study of mitochondrial decline in skin cells leading to skin aging and even obesity. Also, a new Atopic Dermatitis Journal Club examines combination therapy with dupiluma